PT  - JOURNAL ARTICLE
AU  - Zhang, Meng
AU  - Liu, Ergang
AU  - Cui, Yanna
AU  - Huang, Yongzhuo
TI  - Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
AID  - 10.20892/j.issn.2095-3941.2017.0054
DP  - 2017 Aug 01
TA  - Cancer Biology and Medicine
PG  - 212--227
VI  - 14
IP  - 3
4099  - http://www.cancerbiomed.org/content/14/3/212.short
4100  - http://www.cancerbiomed.org/content/14/3/212.full
SO  - Cancer Biol Med2017 Aug 01; 14
AB  - Multidrug resistance (MDR) is a major obstacle to successful cancer treatment and is crucial to cancer metastasis and relapse. Combination therapy is an effective strategy for overcoming MDR. However, the different pharmacokinetic (PK) profiles of combined drugs often undermine the combination effect in vivo, especially when greatly different physicochemical properties (e.g., those of macromolecules and small drugs) combine. To address this issue, nanotechnology-based codelivery techniques have been actively explored. They possess great advantages for tumor targeting, controlled drug release, and identical drug PK profiles. Thus, a powerful tool for combination therapy is provided, and the translation from in vitro to in vivo is facilitated. In this review, we present a summary of various combination strategies for overcoming MDR and the nanotechnology-based combination therapy.